You are here

Repatha

Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too

Endpoints

Flag link:

ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha

ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha

Fierce Pharma

Flag link:

ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients

ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients

Fierce Pharma

clinical trials

Flag link:

Two Big Drug Flops Show How Health-Care Economics Have Changed

Two Big Drug Flops Show How Health-Care Economics Have Changed

Bloomberg

Flag link:

AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients

AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients

Fierce Pharma

PCSK9 inhibitor

Flag link:

Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020

Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020

Yahoo/Reuters

Flag link:

MedCo's PCSK9 challenger steals the show at ESC with winning data

MedCo's PCSK9 challenger steals the show at ESC with winning data

Fierce Pharma

Medicines Company

PCSK9 inhibitors

European Society of Cardiology

Flag link:

Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha

Fierce Pharma

PCSK9 inhibitors

Flag link:

Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

Fierce Pharma

Medicines Company

PCSK9 inhibitors

Flag link:

German court blocks sale of Sanofi, Regeneron cholesterol drug

German court blocks sale of Sanofi, Regeneron cholesterol drug

Biopharma Dive

Flag link:

Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

Investors Business Daily

clinical trials

Flag link:

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

Biopharma Dive

PCSK9 inhibitors

Flag link:

Amgen touts lowered prices for Repatha delivery devices

Amgen touts lowered prices for Repatha delivery devices

Drug Delivery Business News

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%

In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%

Forbes

Flag link:

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Fierce Pharma

PCSK9 inhibitors

Flag link:

Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

NASDAQ.com

type 2 diabetes

hypercholesterolemia

Flag link:

Are These Disappointing Drugs Back on Track to Billions?

Are These Disappointing Drugs Back on Track to Billions?

Motley Fool

PCSK9 inhibitors

Flag link:

Amgen focuses on migraine launch as growth remains slow

Amgen focuses on migraine launch as growth remains slow

Biopharma Dive

Flag link:

Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?

Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?

Xtalks

outcome-based pricing

Flag link:

Pages